Taurolidine–citrate lock solution for the prevention of central line‐associated bloodstream infection in paediatric haematology–oncology and gastrointestinal failure patients with high baseline central‐line associated bloodstream infection rates

Abstract

TCS usage was highly successful in CLABSI reduction by 80% in all patients, 90% in H/O and 70% in GI patients. In patients with high baseline CLABSI rates, TCS is an effective catheter-lock therapy to reduce CLABSI rates in paediatric patients.